Mural Oncology (NASDAQ:MURA) Trading 3.2% Higher – What’s Next?

Mural Oncology PLC (NASDAQ:MURA)’s stock price rose 3.2% during mid-day trading on Friday . The stock traded as high as $2.64 and last traded at $2.59. Approximately 127,240 shares traded hands during trading, a decline of 90% from the average daily volume of 1,290,085 shares. The stock had previously closed at $2.51.

Wall Street Analysts Forecast Growth

A number of analysts have commented on MURA shares. HC Wainwright reduced their price target on Mural Oncology from $18.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, March 26th. Jones Trading reiterated a “hold” rating on shares of Mural Oncology in a research note on Tuesday, March 25th. Morgan Stanley lowered shares of Mural Oncology from an “overweight” rating to an “equal weight” rating in a report on Tuesday, March 25th. Finally, Raymond James Financial cut shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 target price on the stock. in a research note on Tuesday, March 25th.

Mural Oncology Trading Up 3.2%

The company has a market cap of $44.73 million, a PE ratio of -0.34 and a beta of 3.03. The business’s 50 day moving average is $2.58 and its two-hundred day moving average is $2.98.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.93) EPS for the quarter, beating analysts’ consensus estimates of ($2.12) by $0.19. As a group, equities research analysts predict that Mural Oncology PLC will post -7.54 EPS for the current fiscal year.

Institutional Trading of Mural Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in Mural Oncology in the 4th quarter worth approximately $129,000. Two Sigma Advisers LP purchased a new position in shares of Mural Oncology in the fourth quarter worth $84,000. Renaissance Technologies LLC lifted its holdings in shares of Mural Oncology by 17.4% in the fourth quarter. Renaissance Technologies LLC now owns 238,465 shares of the company’s stock worth $768,000 after buying an additional 35,403 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Mural Oncology during the fourth quarter worth $181,000. Finally, Two Sigma Investments LP grew its stake in Mural Oncology by 12.0% during the fourth quarter. Two Sigma Investments LP now owns 65,150 shares of the company’s stock valued at $210,000 after acquiring an additional 6,993 shares in the last quarter. Institutional investors own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.